What is Kytopen?
Kytopen is at the forefront of biotechnology, developing innovative non-viral cell engineering and gene delivery technologies. Its core offering, the Flowfect platform, facilitates the efficient delivery of genetic materials like DNA and mRNA into living cells through a scalable, continuous flow process. This technology aims to accelerate and standardize cell therapy research and production, making cell modification faster, more consistent, and suitable for large-scale biomanufacturing. The company collaborates with researchers and biotech organizations to streamline complex laboratory workflows and advance therapeutic development.
How much funding has Kytopen raised?
Kytopen has raised a total of $33.6M across 2 funding rounds:
Angel/Seed
$3.6M
Series A
$30M
Angel/Seed (2019): $3.6M with participation from Horizons Ventures and The Engine
Series A (2021): $30M led by Northpond Ventures, Mass Ventures, and Horizon Ventures
Key Investors in Kytopen
Northpond Ventures
Northpond Ventures is a venture capital firm that typically invests in companies at the intersection of life sciences and technology, focusing on transformative innovations.
Mass Ventures
MassVentures is dedicated to empowering entrepreneurs by providing essential resources to transform their ideas into reality. The company collaborates closely with startups and small businesses, offering guidance on business planning, fundraising, and more.
Horizon Ventures
Horizon Ventures focuses on providing early stage funding for high-quality technology startup companies in areas such as internet business-to-business, internet business-to-consumer, application server and desktop software solutions, and telecommunications.
What's next for Kytopen?
With the recent major enterprise-level funding, Kytopen is poised for significant expansion and further development of its Flowfect platform. This capital injection will likely fuel advancements in scaling its technology for broader biomanufacturing applications and potentially support clinical trial advancements for cell therapies. The company's focus on improving the efficiency and consistency of cell modification positions it as a key player in the rapidly growing cell therapy market, with strategic investments expected to drive innovation and market penetration.
See full Kytopen company page
